Press Releases for GSK

Press Releases
Denture cream zinc allegedly harmful
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results; Provides 2010 Financial Guidance and 2012 Financial Targets
NanoBio Awarded Key Patent Covering Vaccine and Anti-Infective Product Platforms
Tykerb approved for use with Femara
Canada donating excess H1N1 vaccine
MWB Consulting Joins SAFE-BioPharma Association
Most unhappy with eating habits of others
Accelerate National Internet Exchange of Health and Patient Medical Information Using Existing Approaches, Expert Advises
Oxford Outcomes Joins SAFE-BioPharma Association
Santa's Identity Verified via Digital Identity-Focused Holiday Greeting From SAFE-BioPharma
Seasonal flu vaccine supplies spur worries
FDA approves additional H1N1 vaccine
Auditor: Canada disaster planning is poor
Vaccine-short Canada exporting 'surplus'
Largest malaria vaccine trial under way
Canada's H1N1 flu vaccine running short
FDA OK's new leukemia treatment
Procter &Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio
FDA OK's pediatric seasonal flu vaccine
FDA approves new kidney cancer treatment
Cervical cancer vaccine approved for sale
Pronova BioPharma Receives 2009 Frost &Amp; Sullivan Award for Excellence in Financial &Amp; Risk Management
Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
Journal: Canada behind on H1N1 vaccine
85% Profitable Trades Keep Galtstock.Com Subscribers Very Happy
Tennis Legend John McEnroe Tells Men to 'Get Serious' About Prostate Cancer
FDA reviews Xenical, Alli safety issue
GSK Advisory: Warehouse Theft
FDA approves Hiberix vaccine for kids
Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy
FDA approves Hiberix flu vaccine for kids
Video: FDA Approves GSK's Hib Vaccine, Hiberix(R)
Pharmerging Versus Mature Pharmaceutical Markets: Where Is Pharma Going? Where Is Pharma Growing? -- an Industrial Info News Alert
Canada orders 50M doses of H1N1 vaccine
StockPreacher.com Issues Trading Outlook for ViroPharma Inc.
NYSE Euronext to Host Global Virtual Investor Forum With Leading Non-U.S. Companies: "Seeking Opportunity in a Challenging Global Market"
NYSE Euronext to Host Global Virtual Investor Forum With Leading non-U.S. Companies: “Seeking Opportunity in a Challenging Global Market”
Theravance Reports Second Quarter 2009 Financial Results
Some of Canada's H1N1 vaccine for export
ParagonReport.Com Complimentary Market Update on MRK, BMY, PFE and GSK
GlaxoSmithKline Completes Acquisition of Stiefel
GSK - Improving Performance to Continue in Second Half
Quest Diagnostics Reports Strong Performance in Second Quarter 2009 ; - Total Revenues of $1.9 Billion, Up 3.5%;; - Diluted Earnings of $1.00 Per Share, Up 20%;; - 2009 EPS Outlook Increased to Between $3.70 and $3.80
Quest Diagnostics Reports Strong Performance in Second Quarter 2009
Benlysta shows promise in treating lupus
Canada to have H1N1 flu vaccine surplus
GSK to Announce Q2 Results July 22, 2009
ParagonReport.Com Complimentary Analyst Opinion on PFE and GSK
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
FDA to require warnings for Chantix, Zyban
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
Aileron Therapeutics Closes $40 Million Series D Financing
Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
Cleveland Attorney of Anderson Law Offices Says Avandia Study Based On "Junk Science"
GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL®
FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
Eurand Announces FDA Approval of EUR-1048 (Lamictal(R) ODT(TM)), Co-Developed With GlaxoSmithKline
Highland Distressed Opportunities, Inc. Announces March 31, 2009 Quarterly Financial Results
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL®
Phase II Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009 - Apr 21 2009 10:56AM
Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009 - Apr 21 2009 7:54AM
Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results
Research and Markets: Global Strategic Report Analyzes the Anti-Aging Products in Millions of US$ and Profiles 799 of the Most Prolific Companies in the Industry
GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) for First-Line Treatment of Metastatic Breast Cancer in Europe, US
GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
CERVARIX(R) U.S. Regulatory Update
John McEnroe is Serious About Getting Men to Take the '50 Over 50 Prostate Health Challenge'
Prasco Selected as GSK’s Generics Marketing and Distribution Agent
Prasco Selected as GSK's Generics Marketing and Distribution Agent
Research and Markets: Brush Up on the Oral Hygiene Products Industry With This Latest Global Strategic Business Report Featuring Forecasts From 2001 to 2015 - Mar 6 2009 11:56PM
Research and Markets: Brush Up on the Oral Hygiene Products Industry With This Latest Global Strategic Business Report Featuring Forecasts From 2001 to 2015 - Mar 6 2009 10:04AM
Ample Supplies of Relenza Available as Flu Season Peaks
Zacks Analyst Blog Highlights: Pozen, Inc., GlaxoSmithKline, AstraZeneca, Grupo Aeroportuario Del Sureste and Citigroup
Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
Activplant Corporation Announces Global Agreement with GlaxoSmithKline
Corporate Leaders Receive Ninth Annual Emerald Asset Management "E-3 Awards"
GlaxoSmithKline Reports Q4 and Year End Results 2008
GSK Notice of Full Year Financial Results Announcement
GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
BenchmarkJournal.Com (Complimentary) Analyst Review for CTX, TXT, UIS and GSK
Ligand Enters into Exclusive License Agreement with GlaxoSmithKline to License Rights to LGD-4665 and other Ligand Thrombopoietin (TPO) Molecules
GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance
GlaxoSmithKline Further Extends Tender Offer to Acquire Genelabs Technologies, Inc.
GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
Research and Markets: A Comprehensive Analysis of the Republic of Korea's Drug Delivery Devices Market: Discover Investment Opportunities and Forecasts to 2012 - Dec 11 2008 12:51AM
Eli Lilly and Company Joins SAFE-BioPharma Association
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)